SCHEMBL14745197

SCHEMBL14745197

C/C=C\c1c(-c2ccc(N(C)C)cc2)[nH]c(=O)c(C(=O)OC)c1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.36
TLR9 Q9NR96 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
USP2 O75604 1/20 0.36
GSK3B P49841 1/20 0.35
TSHR P16473 2/20 0.35
SMN1; SMN2 Q16637 3/20 0.34
KDM4E B2RXH2 3/20 0.34
MAPT P10636 2/20 0.34
MAPK1 P28482 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
LMNA P02545 1/20 0.34
GABRG2 P18507 2/20 0.34
GABRB3 P28472 2/20 0.34
GABRA3 P34903 2/20 0.34
GABRA2 P47869 2/20 0.34
GABRA1 P14867 1/20 0.34
LRP6 O75581 1/20 0.34
ALDH1A1 P00352 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745198 1.00 ATM (0.36) ATMTLR9L3MBTL1USP2GSK3B
SCHEMBL14745199 1.00 ATM (0.36) ATMTLR9L3MBTL1USP2GSK3B
SCHEMBL16568028 0.87 MAPT (0.36) L3MBTL1GSK3BSMN1; SMN2KDM4EMAPT
SCHEMBL14745288 0.87 MAPT (0.36) L3MBTL1GSK3BSMN1; SMN2KDM4EMAPT
SCHEMBL14744726 0.87 MAPT (0.36) L3MBTL1GSK3BSMN1; SMN2KDM4EMAPT
SCHEMBL16568202 0.78 MAPT (0.39) ATMTLR9L3MBTL1USP2GSK3B
SCHEMBL16568294 0.75 RNASEH1 (0.44) TSHRSMN1; SMN2KDM4EMAPTGABRG2
SCHEMBL16567873 0.72 ALDH1A1 (0.50) TSHRSMN1; SMN2KDM4EMAPTMAPK1
SCHEMBL27962152 0.70 GSK3B (0.41) GSK3BTSHRSMN1; SMN2KDM4EMAPT
SCHEMBL16568114 0.70 ALOX5 (0.43) L3MBTL1USP2GSK3BTSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9650395-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2017-05-16 US disclosed
US-20150080362-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-03-19 US disclosed
EP-2750505-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033240-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150080362-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP ATM 4210/4885TLR9 392/4885L3MBTL1 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.